Results 141 to 150 of about 1,055,467 (319)
Molecular Oncology, EarlyView.Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen +11 more
wiley +1 more source
, 2018 Therapeutics Letter 116 examines a new drug therapy for cystic fibrosis (CF). Conclusions: Lumacaftor/ivacaftor (Orkambi) is a new combination drug for the treatment of CF.
Therapeutics Initiative (University of British Columbia)
core
Molecular Oncology, EarlyView.Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau +36 more
wiley +1 more source
, 1996 Therapeutics Letter 12 focusses on the optimal management of asthma in the primary care setting. Conclusions: regular inhaled corticosteroids are the main therapy in asthmatic patients with frequent symptoms or exacerbations.
Therapeutics Initiative (University of British Columbia)
core
Molecular Oncology, EarlyView.Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang +12 more
wiley +1 more source
, 1995 Therapeutics Letter 8 reviews drugs of choice in the treatment of hypertension. Conclusions: It is up to the clinician, through systematic therapeutic trials, to identify the drug(s) which are efficacious, well tolerated in low doses, convenient, and ...
Therapeutics Initiative (University of British Columbia)
core
Interrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer
Molecular Oncology, EarlyView.COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...
Rodrigo Dienstmann +61 more
wiley +1 more source
, 2001 Therapeutics Letter 40 considers the impact of direct to consumer advertising (DTCA) on finasteride for male pattern hair loss. Conclusions: DTCA appears to increase drug sales and adds to the pressure on busy clinicians. Before yielding to this pressure,
Therapeutics Initiative (University of British Columbia)
core
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source
, 2015 Therapeutics Letter 97 examines intravenous (IV) iron for severe iron deficiency. Conclusions Intravenous iron markedly benefits appropriately selected people with chronic severe iron deficiency.
Therapeutics Initiative (University of British Columbia)
core